Do you know the difference between a biosimilar, a biobetter and a next generation antibody?
There is much confusion through the antibody industry about the exact definition of these molecules, leading to inaccurate application and more confusion!
Dr Alain Beck, Head of Physico-Chemistry Department at the Centre d'Immunologie Pierre Fabre and Associate Editor of the journal, mAbs, opened the 7th annual European Antibody Congress 2011 by clearly defining each antibody classification, before moving onto highlighting through case studies, the impact structure-function relationship understanding can have on antibody development.
To find out these definitions and also gain an overview of the most recent advances in antibody molecular design, watch Dr Alain Beck's full presentation below:
If you are looking to develop your understanding of the biosimilars market, regulatory requirements and network within this exciting space then you need to check out the 2012 World Biosimilar Congress, DOWNLOAD the World Biosimilar Congress Brochure
Do you want to find out more?
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D